The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: An application of the international classification of functioning, disability and health

Kate Miller, Aaron Yarlas, Warren Wen, Bradley Dain, Shau Yu Lynch, Steven R. Ripa, Joseph V. Pergolizzi, Robert Raffa

Research output: Contribution to journalArticle

Abstract

Objectives: The Buprenorphine Transdermal Delivery System (BTDS) is indicated for reduction of pain in moderate to severe chronic low back pain (CLBP), which can affect patients' ability to perform routine activities of daily living (ADLs). This post hoc analysis of clinical trial data examines the impact of BTDS treatment on CLBP patients' ability to perform ADLs that relate to functioning with low back pain. Methods: Data are drawn from a multicenter, enriched enrollment, randomized, placebo-controlled, double-blind 12-week trial of BTDS for pain control among opioid-naive patients with moderate to severe CLBP. The 23 selected ADLs are those that (1) appear in the Low Back Pain Core Set of the International Classification of Functioning, Disability and Health and (2) link to the content of 3 patient-reported outcome instruments administered during the trial. Logistic regression models estimated the odds ratios (ORs) of BTDS patients' ability to perform each ADL at 12 weeks, controlling for baseline ability, relative to placebo. Results: The ORs for 10 ADLs related to sleeping, lifting, bending, and working reached multiplicity-adjusted statistical significance and indicated a greater ability to perform ADLs among BTDS users than among the placebo group. These 10 ORs ranged from 1.9 (no physical health-related restrictions on the kind of work performed) to 2.4 (being able to sleep undisturbed by pain). Discussion: These results suggest that for patients with moderate to severe CLBP, 12 weeks use of BTDS improves the ability to carry out certain ADLs related to sleeping, lifting, bending, and working.

Original languageEnglish (US)
Pages (from-to)1015-1022
Number of pages8
JournalClinical Journal of Pain
Volume30
Issue number12
DOIs
StatePublished - 2014

Fingerprint

International Classification of Functioning, Disability and Health
Buprenorphine
Activities of Daily Living
Aptitude
Low Back Pain
Odds Ratio
Placebos
Pain
Logistic Models
Opioid Analgesics
Sleep
Clinical Trials
Health

Keywords

  • Activities of daily living
  • Buprenorphine
  • Butrans
  • Low back pain
  • Opioid treatment

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Medicine(all)

Cite this

The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain : An application of the international classification of functioning, disability and health. / Miller, Kate; Yarlas, Aaron; Wen, Warren; Dain, Bradley; Lynch, Shau Yu; Ripa, Steven R.; Pergolizzi, Joseph V.; Raffa, Robert.

In: Clinical Journal of Pain, Vol. 30, No. 12, 2014, p. 1015-1022.

Research output: Contribution to journalArticle

Miller, Kate ; Yarlas, Aaron ; Wen, Warren ; Dain, Bradley ; Lynch, Shau Yu ; Ripa, Steven R. ; Pergolizzi, Joseph V. ; Raffa, Robert. / The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain : An application of the international classification of functioning, disability and health. In: Clinical Journal of Pain. 2014 ; Vol. 30, No. 12. pp. 1015-1022.
@article{53bb93ff3b2444a9b40d310ff84b4adf,
title = "The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: An application of the international classification of functioning, disability and health",
abstract = "Objectives: The Buprenorphine Transdermal Delivery System (BTDS) is indicated for reduction of pain in moderate to severe chronic low back pain (CLBP), which can affect patients' ability to perform routine activities of daily living (ADLs). This post hoc analysis of clinical trial data examines the impact of BTDS treatment on CLBP patients' ability to perform ADLs that relate to functioning with low back pain. Methods: Data are drawn from a multicenter, enriched enrollment, randomized, placebo-controlled, double-blind 12-week trial of BTDS for pain control among opioid-naive patients with moderate to severe CLBP. The 23 selected ADLs are those that (1) appear in the Low Back Pain Core Set of the International Classification of Functioning, Disability and Health and (2) link to the content of 3 patient-reported outcome instruments administered during the trial. Logistic regression models estimated the odds ratios (ORs) of BTDS patients' ability to perform each ADL at 12 weeks, controlling for baseline ability, relative to placebo. Results: The ORs for 10 ADLs related to sleeping, lifting, bending, and working reached multiplicity-adjusted statistical significance and indicated a greater ability to perform ADLs among BTDS users than among the placebo group. These 10 ORs ranged from 1.9 (no physical health-related restrictions on the kind of work performed) to 2.4 (being able to sleep undisturbed by pain). Discussion: These results suggest that for patients with moderate to severe CLBP, 12 weeks use of BTDS improves the ability to carry out certain ADLs related to sleeping, lifting, bending, and working.",
keywords = "Activities of daily living, Buprenorphine, Butrans, Low back pain, Opioid treatment",
author = "Kate Miller and Aaron Yarlas and Warren Wen and Bradley Dain and Lynch, {Shau Yu} and Ripa, {Steven R.} and Pergolizzi, {Joseph V.} and Robert Raffa",
year = "2014",
doi = "10.1097/AJP.0000000000000068",
language = "English (US)",
volume = "30",
pages = "1015--1022",
journal = "Clinical Journal of Pain",
issn = "0749-8047",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain

T2 - An application of the international classification of functioning, disability and health

AU - Miller, Kate

AU - Yarlas, Aaron

AU - Wen, Warren

AU - Dain, Bradley

AU - Lynch, Shau Yu

AU - Ripa, Steven R.

AU - Pergolizzi, Joseph V.

AU - Raffa, Robert

PY - 2014

Y1 - 2014

N2 - Objectives: The Buprenorphine Transdermal Delivery System (BTDS) is indicated for reduction of pain in moderate to severe chronic low back pain (CLBP), which can affect patients' ability to perform routine activities of daily living (ADLs). This post hoc analysis of clinical trial data examines the impact of BTDS treatment on CLBP patients' ability to perform ADLs that relate to functioning with low back pain. Methods: Data are drawn from a multicenter, enriched enrollment, randomized, placebo-controlled, double-blind 12-week trial of BTDS for pain control among opioid-naive patients with moderate to severe CLBP. The 23 selected ADLs are those that (1) appear in the Low Back Pain Core Set of the International Classification of Functioning, Disability and Health and (2) link to the content of 3 patient-reported outcome instruments administered during the trial. Logistic regression models estimated the odds ratios (ORs) of BTDS patients' ability to perform each ADL at 12 weeks, controlling for baseline ability, relative to placebo. Results: The ORs for 10 ADLs related to sleeping, lifting, bending, and working reached multiplicity-adjusted statistical significance and indicated a greater ability to perform ADLs among BTDS users than among the placebo group. These 10 ORs ranged from 1.9 (no physical health-related restrictions on the kind of work performed) to 2.4 (being able to sleep undisturbed by pain). Discussion: These results suggest that for patients with moderate to severe CLBP, 12 weeks use of BTDS improves the ability to carry out certain ADLs related to sleeping, lifting, bending, and working.

AB - Objectives: The Buprenorphine Transdermal Delivery System (BTDS) is indicated for reduction of pain in moderate to severe chronic low back pain (CLBP), which can affect patients' ability to perform routine activities of daily living (ADLs). This post hoc analysis of clinical trial data examines the impact of BTDS treatment on CLBP patients' ability to perform ADLs that relate to functioning with low back pain. Methods: Data are drawn from a multicenter, enriched enrollment, randomized, placebo-controlled, double-blind 12-week trial of BTDS for pain control among opioid-naive patients with moderate to severe CLBP. The 23 selected ADLs are those that (1) appear in the Low Back Pain Core Set of the International Classification of Functioning, Disability and Health and (2) link to the content of 3 patient-reported outcome instruments administered during the trial. Logistic regression models estimated the odds ratios (ORs) of BTDS patients' ability to perform each ADL at 12 weeks, controlling for baseline ability, relative to placebo. Results: The ORs for 10 ADLs related to sleeping, lifting, bending, and working reached multiplicity-adjusted statistical significance and indicated a greater ability to perform ADLs among BTDS users than among the placebo group. These 10 ORs ranged from 1.9 (no physical health-related restrictions on the kind of work performed) to 2.4 (being able to sleep undisturbed by pain). Discussion: These results suggest that for patients with moderate to severe CLBP, 12 weeks use of BTDS improves the ability to carry out certain ADLs related to sleeping, lifting, bending, and working.

KW - Activities of daily living

KW - Buprenorphine

KW - Butrans

KW - Low back pain

KW - Opioid treatment

UR - http://www.scopus.com/inward/record.url?scp=84927911415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927911415&partnerID=8YFLogxK

U2 - 10.1097/AJP.0000000000000068

DO - 10.1097/AJP.0000000000000068

M3 - Article

C2 - 24394747

AN - SCOPUS:84927911415

VL - 30

SP - 1015

EP - 1022

JO - Clinical Journal of Pain

JF - Clinical Journal of Pain

SN - 0749-8047

IS - 12

ER -